Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.

Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC.

Blood. 2005 Aug 1;106(3):1042-7. Epub 2005 Apr 12.

2.

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs.

Nakanishi C, Toi M.

Nat Rev Cancer. 2005 Apr;5(4):297-309. Review.

PMID:
15803156
3.

Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.

Song L, Coppola D, Livingston S, Cress D, Haura EB.

Cancer Biol Ther. 2005 Mar;4(3):267-76. Epub 2005 Mar 20.

PMID:
15753661
4.
5.

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.

Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE.

N Engl J Med. 2004 Aug 5;351(6):533-42.

6.

NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP.

Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O, Häcker G, Dittrich-Breiholz O, Kracht M, Scheurich P, Wajant H.

J Cell Biol. 2004 Aug 2;166(3):369-80.

7.

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.

Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, Rubnitz JE, Razzouk BI, Howard SC, Hudson MM, Cheng C, Kun LE, Raimondi SC, Behm FG, Downing JR, Relling MV, Evans WE; Total Therapy Study XIIIB at St Jude Children's Research Hospital.

Blood. 2004 Nov 1;104(9):2690-6. Epub 2004 Jul 13.

8.

Discovery of novel molecular classification schemes and genes predictive of outcome in leukemia.

Willman CL.

Hematol J. 2004;5 Suppl 3:S138-43. Review. No abstract available.

PMID:
15190296
9.

Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays.

Willenbrock H, Juncker AS, Schmiegelow K, Knudsen S, Ryder LP.

Leukemia. 2004 Jul;18(7):1270-7.

PMID:
15152267
10.

Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling.

Weston VJ, Austen B, Wei W, Marston E, Alvi A, Lawson S, Darbyshire PJ, Griffiths M, Hill F, Mann JR, Moss PA, Taylor AM, Stankovic T.

Blood. 2004 Sep 1;104(5):1465-73. Epub 2004 May 13.

11.

Acute lymphoblastic leukemia.

Pui CH, Relling MV, Downing JR.

N Engl J Med. 2004 Apr 8;350(15):1535-48. Review. No abstract available.

PMID:
15071128
12.

In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.

Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER, Slater RM, Harbott J, den Boer ML, Ludwig WD, Haas OA, Janka-Schaub GE, Pieters R.

Leukemia. 2004 Mar;18(3):521-9.

PMID:
14712291
13.

A global test for groups of genes: testing association with a clinical outcome.

Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC.

Bioinformatics. 2004 Jan 1;20(1):93-9.

PMID:
14693814
14.

Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations.

Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M.

J Biol Chem. 2003 Nov 14;278(46):45082-93. Epub 2003 Aug 29.

15.

Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.

Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Körholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJ, Kamps WA, Van der Does-Van den Berg A, Van Wering ER, Veerman AJ, Janka-Schaub GE.

J Clin Oncol. 2003 Sep 1;21(17):3262-8.

PMID:
12947061
16.

Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia.

Holleman A, den Boer ML, Kazemier KM, Janka-Schaub GE, Pieters R.

Blood. 2003 Dec 15;102(13):4541-6. Epub 2003 Aug 14.

17.

APAF-1-ALT, a novel alternative splicing form of APAF-1, potentially causes impeded ability of undergoing DNA damage-induced apoptosis in the LNCaP human prostate cancer cell line.

Ogawa T, Shiga K, Hashimoto S, Kobayashi T, Horii A, Furukawa T.

Biochem Biophys Res Commun. 2003 Jun 27;306(2):537-43.

PMID:
12804598
18.

Classification of pediatric acute lymphoblastic leukemia by gene expression profiling.

Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, Liu HC, Mahfouz R, Raimondi SC, Lenny N, Patel A, Downing JR.

Blood. 2003 Oct 15;102(8):2951-9. Epub 2003 May 1.

19.

Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells.

Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, Relling MV, Evans WE.

Nat Genet. 2003 May;34(1):85-90. Erratum in: Nat Genet. 2003 Jun;34(2):231.

PMID:
12704389
20.

Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.

Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, Look AT.

Blood. 2003 Jul 1;102(1):262-8. Epub 2003 Mar 13.

Supplemental Content

Support Center